[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406622-105":59,"doc-detail-406622-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-survival-after-treatment-of-gastric-cancer-with-s-1-plus-oxaliplatin-regimen-and-sintilimab-a-case-report","Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab - A case report","","BACKGROUND: Metastatic gastric cancer primarily depends on chemotherapy, which is often combined with immunotherapy, yet outcomes remain limited. CASE SUMMARY: A patient with metastatic gastric cancer received first-line S-1 plus oxaliplatin with sintilimab, then maintenance S-1 and sintilimab. After 6 months, partial response showed 71.7% target lesion reduction, progressing to 76.3% at 13 months. Treatment paused for 6 months due to pulmonary infection; later reassessment still showed tumor regression with 79.4% reduction and 23 months progression-free survival. CONCLUSION: Sintilimab with chemotherapy improved progression-free survival and merits further study.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-survival-after-treatment-of-gastric-cancer-with-s-1-plus-oxaliplatin-regimen-and-sintilimab-a-case-report/406622/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-survival-after-treatment-of-gastric-cancer-with-s-1-plus-oxaliplatin-regimen-and-sintilimab-a-case-report/406622.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment sequence was used in the reported case of metastatic gastric cancer?","Question",{"text":112,"@type":113},"The patient received first-line S-1 plus oxaliplatin combined with sintilimab, followed by maintenance therapy with S-1 and sintilimab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the tumor respond over time according to the case report?",{"text":117,"@type":113},"A partial response was observed after 6 months with a 71.7% reduction in target lesions, reaching 76.3% at 13 months. Even after a treatment pause for pulmonary infection, reassessment showed continued regression with a 79.4% reduction.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the progression-free survival reported from diagnosis to the time of reporting?",{"text":121,"@type":113},"Progression-free survival reached 23 months from diagnosis to the reported date.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},406622,1790809281,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| W | J | G | O | World Journal of\u003Cbr>Gastrointestinal Oncology |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastrointest Oncol 2025 December 15; 17(12): 112853  \nDOI: 10.4251/wjgo.v17.i12.112853 ISSN 1948-5204 (online)  \nCASE REPORT  \nLong-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report  \nJun Pan, Ping Li, Yu-He Zhou, Ting-Ting Pan, Yi-Tian Chen, Xiao-Yuan Chu  \nSpecialty type: Oncology  \nProvenance and peer review:  \nUnsolicited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B  \nNovelty: Grade B  \nCreativity or Innovation: Grade C  \nScientific Significance: Grade D  \nP-Reviewer: Malmir I, PhD, Post Doctoral Researcher, United States  \nReceived: August 8, 2025  \nRevised: September 5, 2025  \nAccepted: October 20, 2025  \nPublished online: December 15, 2025  \nProcessing time: 126 Days and 2.6 Hours  \nJun Pan, Yi-Tian Chen, Xiao-Yuan Chu, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China  \nPing Li, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China  \nYu-He Zhou, Ting-Ting Pan, Department of General Medicine, Jinling Hospital, Medical School  \nof Nanjing University, Nanjing 210002, Jiangsu Province, China Co-first authors: Jun Pan and Ping Li.  \nCo-corresponding authors: Yi-Tian Chen and Xiao-Yuan Chu.  \nCorresponding author: Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, [China.](China. chuxiaoyuan0@163.com)[ chuxiaoyuan0@163.com](China. chuxiaoyuan0@163.com)  \nAbstract  \nBACKGROUND  \nTreatment of metastatic gastric cancer (mGC) relies primarily on chemotherapy, which can be effectively combined with immunotherapy. Despite these interventions, overall survival remains suboptimal.  \nCASE SUMMARY  \nWe report a patient with mGC who received S-1 plus oxaliplatin with sintilimabas first-line therapy, followed by maintenance therapy with S-1 and sintilimab. After 6 months, a partial response was observed, with a 71.7% reduction in the target lesion. After 13 months, the reduction reached 76.3% . Treatment was temporarily paused for 6 months due to a pulmonary infection. Upon re-evaluation 6 months later, the tumor continued to regress, with a 79.4% reduction in the target lesion. The original regimen was then resumed. From diagnosis to date, progression-free survival has reached 23 months.  \nCONCLUSION  \nSintilimab combined with chemotherapy demonstrated improved progressionfree survival and warrants further investigation in mGC.  \nKey Words: Metastatic gastric cancer; Sintilimab; Immunotherapy; Chemotherapy; Progression-free survival; Case report  \n WJGO  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 15, 2025  Volume 17  Issue 12   \nPan J et al. Long-term survival after treatment of mGC  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \nCore Tip: Chemotherapy combined with immunotherapy is the standard first-line treatment for metastatic gastric cancer. However, the first-line median progression-free survival is only about 7 months. This article reports a case of metastatic gastric cancer in which the patient received S-1 plus oxaliplatin regimen with sintilimab, followed by maintenance therapy with S-1 and sintilimab. The patient achieved a partial response and a progression-free survival of 23 months. Moreover, the treatment was temporarily paused for 6 months due to pneumonia. However, upon re-evaluation 6 months later, the tumor continued to regress. This combination therapy has shown encouraging results and warrants further study.  \nCitation: Pan J, Li P, Zhou YH, Pan TT, Chen YT, Chu XY. Long-te","cbCaieBS4RqBi20p","https://ap.wps.com/l/cbCaieBS4RqBi20p","pdf",8017945,"English","# Background\n# Case Summary\n# Conclusion\n# Introduction","[{\"question\":\"What treatment sequence was used in the reported case of metastatic gastric cancer?\",\"answer\":\"The patient received first-line S-1 plus oxaliplatin combined with sintilimab, followed by maintenance therapy with S-1 and sintilimab.\"},{\"question\":\"How did the tumor respond over time according to the case report?\",\"answer\":\"A partial response was observed after 6 months with a 71.7% reduction in target lesions, reaching 76.3% at 13 months. Even after a treatment pause for pulmonary infection, reassessment showed continued regression with a 79.4% reduction.\"},{\"question\":\"What was the progression-free survival reported from diagnosis to the time of reporting?\",\"answer\":\"Progression-free survival reached 23 months from diagnosis to the reported date.\"}]","Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab - A case report | PDF",1790566771,23]